GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hemostemix Inc (OTCPK:HMTXF) » Definitions » ROE % Adjusted to Book Value

HMTXF (Hemostemix) ROE % Adjusted to Book Value : 0.00% (As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Hemostemix ROE % Adjusted to Book Value?

Hemostemix's ROE % for the quarter that ended in Sep. 2024 was 0.00%. Hemostemix's PB Ratio for the quarter that ended in Sep. 2024 was N/A. Hemostemix's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was N/A.

Hemostemix ROE % Adjusted to Book Value Historical Data

The historical data trend for Hemostemix's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hemostemix ROE % Adjusted to Book Value Chart

Hemostemix Annual Data
Trend May14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Hemostemix Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Jun24 Sep24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Hemostemix's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Hemostemix's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hemostemix's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hemostemix's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Hemostemix's ROE % Adjusted to Book Value falls into.


Hemostemix ROE % Adjusted to Book Value Calculation

Hemostemix's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

Hemostemix's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hemostemix ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Hemostemix's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Hemostemix Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hemostemix Inc (OTCPK:HMTXF) » Definitions » ROE % Adjusted to Book Value
Comparable Companies
XCNQ:TRYP TSXV:XRTX XCNQ:CHGX XCNQ:DRUG XCNQ:BETR TSXV:KNE TSXV:RKV TSX:AEZS XCNQ:BLAB TSXV:RP OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
2VF0:Germany HEM:Canada
Address
707 - 7th Avenue SouthWest, Suite 1150, Calgary, AB, CAN, T2P 3H6
Website
https://www.hemostemix.com
Hemostemix Inc is a biotechnology company. The company's principal business activity is developing, manufacturing, and commercializing blood-derived cell therapies for medical conditions. The Company's technology is a platform for developing autologous cell therapies to treat vascular diseases. The Company's clinical stage consists of ACP-01, autologous cell therapy for the treatment of critical limb ischemia.